厄洛替尼在眼表的并发症：3个病例不同转归.

Objective To report three cases of side effects on ocular surface after receiving erlotinib, a kind of epidermal growth factor receptor (EGFR) inhibitor, and to analyze the reasons of different outcomes in these three cases. Methods Case series report. Results The patient in case 1 has been treated with erlotinib orally for nearly seven years. Ocular examination showed punctate epithelial defects on both eyes. Corneal epithelium recovered after eye drops treatment without discontinuation of erlotinib. The patient in case 2 has been treated with erlotinib for over two years. Sterile corneal ulcer with thinning of corneal stroma was present on one eye. After the patient underwent multilayer amniotic membrane transplantations and discontinued erlotinib for one week, the corneal epithelium gradually healed. In these two cases, besides lung cancer, there was no past medical history of hypertension, diabetes or other autoimmune diseases. However, in case 3, the patient had Sjögren syndrome besides lung cancer. After she was treated with erlotinib for over two years, severe ocular surface complications including persistent epithelial defect, corneal melting and perforation were not avoided and a total of four penetrating keratoplasties have been performed. Stable corneal surface was achieved after the erlotinib treatment was paused. Conclusions It is necessary to have detailed eye examinations before EGFR inhibitors treatment in order to exclude underlying ocular surface diseases, especially autoimmune ocular surface diseases. Meanwhile, regular ophthalmic follow-up should be performed during the use of these drugs to avoid severe side effects on ocular surface. [ABSTRACT FROM AUTHOR]